Valley Forge Investment Consultants Inc. ADV Acquires Shares of 83,225 ARS Pharmaceuticals, Inc. $SPRY

Valley Forge Investment Consultants Inc. ADV acquired a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 83,225 shares of the company’s stock, valued at approximately $667,000. ARS Pharmaceuticals accounts for approximately 0.2% of Valley Forge Investment Consultants Inc. ADV’s portfolio, making the stock its 18th biggest holding.

A number of other hedge funds have also modified their holdings of SPRY. Hennion & Walsh Asset Management Inc. purchased a new stake in ARS Pharmaceuticals in the 2nd quarter valued at $1,407,000. Investment Management Associates Inc. ADV acquired a new stake in ARS Pharmaceuticals during the 4th quarter worth $3,629,000. Creek Drive Management Group LLC purchased a new position in ARS Pharmaceuticals during the 4th quarter worth $3,447,000. Rubric Capital Management LP grew its position in ARS Pharmaceuticals by 29.0% during the 1st quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock worth $64,240,000 after purchasing an additional 1,800,000 shares during the last quarter. Finally, UBS Group AG increased its stake in ARS Pharmaceuticals by 235.0% in the fourth quarter. UBS Group AG now owns 2,210,866 shares of the company’s stock valued at $25,757,000 after purchasing an additional 1,550,980 shares during the period. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, insider Eric Karas sold 25,000 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Following the completion of the transaction, the insider directly owned 12,176 shares of the company’s stock, valued at approximately $121,760. This represents a 67.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Alexander A. Fitzpatrick sold 3,355 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $10.00, for a total value of $33,550.00. Following the completion of the sale, the insider directly owned 90,910 shares of the company’s stock, valued at $909,100. This represents a 3.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 33.80% of the stock is currently owned by company insiders.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY opened at $6.30 on Wednesday. The company has a debt-to-equity ratio of 13.72, a current ratio of 3.48 and a quick ratio of 3.28. The stock has a fifty day moving average price of $7.46 and a 200 day moving average price of $8.23. ARS Pharmaceuticals, Inc. has a 1-year low of $4.91 and a 1-year high of $15.09. The company has a market cap of $625.61 million, a PE ratio of -2.89 and a beta of 0.98.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15). The firm had revenue of $33.66 million during the quarter, compared to analysts’ expectations of $31.32 million. ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. Sell-side analysts forecast that ARS Pharmaceuticals, Inc. will post -1.9 EPS for the current year.

Key ARS Pharmaceuticals News

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Positive Sentiment: Some analysts remain constructive on ARS Pharmaceuticals. A Seeking Alpha analysis argues that the new CEO’s cost-reduction initiatives and efforts to increase revenue could improve the company’s outlook. ARS Pharma: New CEO’s Program Of Reducing Costs While Increasing Revenues Makes A Buy
• Neutral Sentiment: Brokerage coverage cited in a separate report gives ARS Pharmaceuticals an average “Moderate Buy” rating, suggesting some analysts still see value despite recent execution and legal concerns. ARS Pharmaceuticals Given Average Rating of Moderate Buy by Brokerages
• Negative Sentiment: Several law firms, including Pomerantz, SBS Law, Gross Law Firm, Faruqi & Faruqi, Robbins and Rosen, are soliciting investors for a securities-fraud class action covering purchases from March 9 through June 24, 2026. The filings allege ARS did not adequately disclose that expanded CVS Caremark formulary coverage for neffy, expected to become effective July 1, 2026, could be delayed until January 2027. Pomerantz Investor Alert
• Negative Sentiment: The allegations claim shareholders suffered losses after the anticipated CVS coverage decision did not occur, with one notice citing an estimated $2.52 per-share decline. The claims remain allegations, and ARS Pharmaceuticals’ ultimate legal and financial exposure has not been established. Levi & Korsinsky Investor Alert
• Negative Sentiment: Investors have until October 5, 2026 to seek appointment as lead plaintiff. The unusually large number of law-firm notices amplifies visibility around the dispute and adds an overhang to SPRY shares.

Analyst Ratings Changes

SPRY has been the subject of a number of research reports. Weiss Ratings cut shares of ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Cantor Fitzgerald raised their price target on ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 28th. Wall Street Zen upgraded ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Leerink Partners reduced their price objective on ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Thursday, June 25th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.20.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.